Redeye comments on IRLAB’s announcement of a fully guaranteed SEK 136m rights issue aimed at advancing its clinical pipeline and strengthening its capital structure. The proceeds, supported by strong shareholder and underwriting commitments, will fund continued development of pirepemat, IRL1117, and IRL757, as well as repay part of the company’s debt.
LÄS MER
